Nov 16,2021

MedRhythms Announces Addition of Global Brain Corporation and Bose Ventures to Series B Round

MedRhythms, a leader in developing prescription digital therapeutics that use sensors, software, and music to measure and improve walking for patients with a neurologic injury or disease, today announced the closing of a Series B extension round, with investment from one of Japan's largest venture capital companies Global Brain with its CVC JGC MIRAI Innovation Fund, and Bose Ventures. The follow-on investment brings the Company’s total Series B financing to $27 million, an increase from their announcement in July.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Nov 29,2021

ieso Raises $53 Million to Address Global Mental Health Crisis With Digital Therapeutics

ieso, a UK leader in digital mental healthcare, announces the completion of its $53 million Series B financing round led by investment firm Morningside, with further new investment from Sony Innovation Fund and existing shareholders IP Group, Molten Ventures and Ananda Impact Ventures.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Dec 02,2021

Digital insulin management company Hygieia closes on $17 million Series B investment round

Hygieia, a digital health company for insulin management, has closed on an initial $17 million Series B investment round, led by Israeli venture capital firm Firstime Ventures, and with participation from existing investors. Hygieia will use the funding to expand partnerships with endocrinology practices and expand access to its unique d-Nav® insulin dose automation technology for people with type 2 diabetes.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Dec 07,2021

Limbix Raises $15 Million in Series A2 Financing

Today, Limbix, a prescription digital therapeutic company developing treatments for adolescent mental health disorders, announced it has raised $15 million in Series A2 financing from both existing and new investors, bringing total funding to date to $31 million. The round was led by GSR Ventures, with participation from existing investors Digital Garage, Storm Ventures, Bixink and DN Capital. Capital raised in the financing will be used by Limbix for commercialization efforts and to double its staff to approximately 60 employees by Q2, 2022. With an expanded product and research team, Limbix plans to accelerate the development and testing of new digital therapeutics targeting other common adolescent mental health disorders.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Dec 06,2021

Pear Therapeutics completes SPAC, begins trading on Nasdaq

Pear Therapeutics began trading on Nasdaq Monday after wrapping up its merger with special-purpose acquisition company Thimble Point Acquisition Corp. last week. The business combination brought in about $175 million, which the company said will be used to capitalize its digital therapeutic products. It's trading under the ticker symbol PEAR.

FUNDING IPO
View Analyst & Ambassador Comments
Go to original news
Dec 10,2021

HypnoVR raises €4.5M in Series A

French digital therapeutics firm HypnoVR has raised €4.5 million in Series A funding for its virtual reality-based medical hypnosis solution for pain and anxiety. The round was led by Theodorus, the Banque des Territoires operating for the French state as part of the Investments for the Future Programme, Akiles and Capital Grand Est via Alsace Création. HypnoVR will use the funds to accelerate its international roll-out and extend the scope of application of its solution.

FUNDING SERIES A

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Feb 25,2021

Medisafe Secures $30M in Series C Funding to Build Future Model of Patient Support

Medisafe, a leading digital therapeutics company creating digital drug companions, today announced that it has raised $30 million in Series C funding with investments led by Sanofi Ventures and ALIVE Israel HealthTech Fund, joined by Leumi Partners, Menorah Mivtachim and Consensus Business Group, previous investors Pitango HealthTech, 7wireVentures, Merck Ventures, Octopus Ventures, lool Ventures, Triventures, Qualcomm Ventures and Ourcrowd. With this new investment Medisafe will further expand its end-to-end solutions supporting patients managing medications and accelerate revenues growth.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Apr 19,2021

Diabetes Reversal Leader Virta Health Raises $133M Series E to Take Type 2 Diabetes Reversal Mainstream

Virta Health, the leader in type 2 diabetes reversal, today announced $133 million of equity financing led by Tiger Global. The latest funding round will accelerate Virta's efforts to drive widespread adoption of its telehealth-powered diabetes reversal treatment. Virta helps people reverse their chronic disease while removing the need for costly medications, including insulin.

FUNDING SERIES E
View Analyst & Ambassador Comments
Go to original news
Feb 01,2022

Jasper Health Raises $25 Million in Series A Funding to Increase Access to Comprehensive Cancer Experience and Care Navigation Platform

Jasper Health, a first-of-its-kind cancer care navigation and experience platform, today announced a $25 million Series A funding round led by General Catalyst. The round, which was joined by new and existing investors Human Capital, W Health Ventures, Redesign Health, and 7wireVentures, brings Jasper Health’s total funding to approximately $31 million.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Mar 11,2022

RefleXion raises $80M for biology-guided radiotherapy tech

RefleXion Medical announced that it closed an $80 million equity financing to support its therapeutic oncology technology. Hayward, California-based RefleXion develops biology-guided radiotherapy (BgRT) for all stages of cancer. The company designed BgRT to transform an injected radiotracer into a unified motion management solution that overcomes the technical limitations currently restricting radiotherapy use to one or two tumors. New investors joining the $80 million round were Ascension Ventures, Catalio Capital Management, Sixty Degree Capital and Hillenbrand Capital Partners.

FUNDING EQUITY FINANCE
View Analyst & Ambassador Comments
Go to original news
Subscribe to FUNDING